Promise Bio

Company Overview

Snapshot

Founded in January 2023 by Ronel Veksler, Promise Bio operates with 11–50 employees. The company has raised $9 million across two funding rounds from two investors. In December 2024, Promise Bio emerged from stealth with an $8.3 million Seed investment.

Business overview

Promise Bio is a Health Tech & Life Sciences company specializing in precision medicine solutions for immune-mediated diseases. The company leverages epiproteomics and artificial intelligence to uncover unique biological insights by analyzing post-translational modifications (PTMs) on standard mass-spectrometry data. Its proprietary PROMISE platform detects up to 45 PTM types simultaneously, enabling maximal knowledge extraction from diverse biological samples. Promise Bio partners with pharmaceutical companies to enhance data-driven drug discovery and development, focusing on identifying functional biomarkers for complex chronic diseases.

Strategic signal

In February 2026, Promise Bio launched the Frontier Epiproteomic Innovation Grant, an R&D access initiative for translational epiproteomic analysis. This program signals the company's commitment to fostering innovation and collaboration within the epiproteomics field, potentially accelerating the adoption of its technology and expanding its research network, which is a strong indicator of future growth and market penetration for investors.

Company Intelligence Q&A

When did Promise Bio emerge from stealth and with what funding?

In December 2024, Promise Bio emerged from stealth with an $8.3 million Seed investment. The company's computational platform uses epiproteomics and AI to predict patient treatment responses and support drug research and development.

What is the core technology behind Promise Bio's platform?

Promise Bio's PROMISE platform utilizes proprietary Comprehensive PTM Profiling to detect up to 45 post-translational modification (PTM) types simultaneously, extracting maximal knowledge from biological data and identifying functional biomarkers from diverse biological samples.

Who are the founders of Promise Bio?

Promise Bio was co-founded by Ronel Veksler, who also serves as the CEO.

What was a significant recent initiative launched by Promise Bio?

In February 2026, Promise Bio launched the Frontier Epiproteomic Innovation Grant, an R&D access initiative designed for translational epiproteomic analysis.